Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation reported a 10% revenue increase in FY2025 to $61.9 million, fueled by the successful launch and commercialization of Emrosi™, a treatment for rosacea. The company improved gross margins and achieved an adjusted EBITDA of $2.9 million, signaling financial strengthening despite a net loss of $11.4 million. Emrosi™ expanded…